Caris Life Sciences Common Stock Share Price CAI

$16.67

▲

1.29

(8.39%)

Last updated on May 29, 2026 at 8:54 pm IST

$₹

Check the interactive Caris Life Sciences Common Stock Stock chart to analyse performance

Caris Life Sciences Common Stock stock performance

as on May 29, 2026 at 8:54 pm IST

Today's Low:$15.46
Today's High:$16.79
$16.67
7.26%
Downside
Day's Volatility :7.92%
Upside
0.71%
52 Weeks Low:$14.19
52 Weeks High:$42.50
$16.67
14.88%
Downside
52 Weeks Volatility :66.61%
Upside
60.78%

Caris Life Sciences Common Stock Stock Returns

Period	Caris Life Sciences, Inc. Common Stock	Index (Russel 2000)
3 Months	-17.23%	0.0%
6 Months	-34.7%	0.0%
1 Year	-40.46%	0.0%
3 Years	-40.46%	0.0%

Caris Life Sciences, Inc. Common Stock Key Stats

Check Caris Life Sciences Common Stock key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$16.67
Open	$15.39
Today's High	$17.03
Today's Low	$16.66
Market Capitalization	$4.3B
Today's Volume	$2.8M
52 Week High	$42.5
52 Week Low	$14.19
Revenue TTM	$907.3M
EBITDA	$129.0M
Earnings Per Share (EPS)	$-2.76
Profit Margin	3.75%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	28.35%

Stock Returns calculator for Caris Life Sciences Common Stock Stock including INR - Dollar returns

The Caris Life Sciences Common Stock stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Caris Life Sciences Common Stock investment value today

Current value as on today

Returns

(0%)

Returns from Caris Life Sciences Common Stock Stock

(0%)

Dollar Impact

(0%)

Indian investors sentiment towards Caris Life Sciences Common Stock Stock

181%

Period: Apr 28, 2026 to May 28, 2026. Change in 30 Days versus previous period

Search interest for Caris Life Sciences Common Stock Stock from India on INDmoney has increased by 181% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Caris Life Sciences, Inc. Common Stock

Name
Holdings %
Name
Holdings %
FMR Inc
10.89%
Sixth Street Partners Management Company, L.P.
6.86%
J. H. Whitney Equity Partners VI, LLC
6.46%
Coatue Management LLC
3.47%
BRAIDWELL LP
2.83%
PointState Capital LP
2.38%

Analyst Recommendation on Caris Life Sciences Common Stock Stock

Rating

Trend

Caris Life Sciences Common Stock Share Price Target

What analysts predicted

Upside of 67.97%

Target:

$28.00

Current:

$16.67

Caris Life Sciences Common Stock share price target is $28.00, a slight Upside of 67.97% compared to current price of $16.67 as per analysts' prediction.

Caris Life Sciences Common Stock Stock Insights

Price Movement
In the last 7 days, CAI stock has moved up by 7.2%

Caris Life Sciences, Inc. Common Stock Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY15

FY16

FY17

FY18

FY19

FY20

FY22

FY23

FY24

FY25

	FY15	Y/Y Change
Revenue	$249.7M	-
Net Income	$26.8M	-
Net Profit Margin	10.75%	-

	FY16	Y/Y Change
Revenue	$294.4M	↑ 17.9%
Net Income	$6.0M	↓ 77.65%
Net Profit Margin	2.04%	↓ 8.71%

	FY17	Y/Y Change
Revenue	$348.4M	↑ 18.36%
Net Income	$72.1M	↑ 1101.6%
Net Profit Margin	20.68%	↑ 18.64%

	FY18	Y/Y Change
Revenue	$432.1M	↑ 24.03%
Net Income	$78.6M	↑ 9.07%
Net Profit Margin	18.19%	↓ 2.49%

	FY19	Y/Y Change
Revenue	$416.5M	↓ 3.6%
Net Income	$31.0M	↓ 60.54%
Net Profit Margin	7.44%	↓ 10.75%

	FY20	Y/Y Change
Revenue	$294.0M	↓ 29.42%
Net Income	$27.7M	↓ 10.57%
Net Profit Margin	9.43%	↑ 1.99%

	FY22	Y/Y Change
Revenue	$258.5M	↓ 12.08%
Net Income	$-320.8M	↓ 1256.84%
Net Profit Margin	-124.12%	↓ 133.55%

	FY23	Y/Y Change
Revenue	$306.1M	↑ 18.43%
Net Income	$-341.4M	↑ 6.42%
Net Profit Margin	-111.53%	↑ 12.59%

	FY24	Y/Y Change
Revenue	$412.3M	↑ 34.67%
Net Income	$-281.9M	↓ 17.43%
Net Profit Margin	-68.38%	↑ 43.15%

	FY25	Y/Y Change
Revenue	$812.0M	↑ 96.97%
Net Income	$-538.0M	↑ 90.84%
Net Profit Margin	-66.25%	↑ 2.13%

Q1 FY21

Q2 FY21

Q3 FY21

Q1 FY24

Q2 FY24

Q1 FY25

Q2 FY25

Q3 FY25

Q4 FY25

Q1 FY26

	Q1 FY21	Q/Q Change
Revenue	$80.8M	-
Net Income	$35.7M	-
Net Profit Margin	44.23%	-

	Q2 FY21	Q/Q Change
Revenue	$85.7M	↑ 6.06%
Net Income	$37.9M	↑ 6.16%
Net Profit Margin	44.28%	↑ 0.05%

	Q3 FY21	Q/Q Change
Revenue	$100.8M	↑ 17.66%
Net Income	$51.2M	↑ 34.82%
Net Profit Margin	50.74%	↑ 6.46%

	Q1 FY24	Q/Q Change
Revenue	$80.7M	↓ 19.98%
Net Income	$-111.0M	↓ 317.04%
Net Profit Margin	-137.62%	↓ 188.36%

	Q2 FY24	Q/Q Change
Revenue	$100.0M	↑ 24.01%
Net Income	$-66.2M	↓ 40.39%
Net Profit Margin	-66.15%	↑ 71.47%

	Q1 FY25	Q/Q Change
Revenue	$120.9M	↑ 20.86%
Net Income	$-102.6M	↑ 54.99%
Net Profit Margin	-84.84%	↓ 18.69%

	Q2 FY25	Q/Q Change
Revenue	$181.4M	↑ 50.02%
Net Income	$-71.8M	↓ 30.02%
Net Profit Margin	-39.58%	↑ 45.26%

	Q3 FY25	Q/Q Change
Revenue	$216.8M	↑ 19.53%
Net Income	$24.3M	↓ 133.88%
Net Profit Margin	11.22%	↑ 50.8%

	Q4 FY25	Q/Q Change
Revenue	$292.9M	↑ 35.07%
Net Income	$82.0M	↑ 236.92%
Net Profit Margin	27.98%	↑ 16.76%

	Q1 FY26	Q/Q Change
Revenue	$216.2M	↓ 26.19%
Net Income	$-510.0K	↓ 100.62%
Net Profit Margin	-0.24%	↓ 28.22%

FY15

FY16

FY17

FY18

FY19

FY20

FY22

FY23

FY24

FY25

	FY15	Y/Y Change
Profit	$125.9M	-

	FY16	Y/Y Change
Profit	$137.5M	↑ 9.21%

	FY17	Y/Y Change
Profit	$169.3M	↑ 23.12%

	FY18	Y/Y Change
Profit	$213.6M	↑ 26.19%

	FY19	Y/Y Change
Profit	$200.5M	↓ 6.14%

	FY20	Y/Y Change
Profit	$184.2M	↓ 8.16%

	FY22	Y/Y Change
Profit	$80.0M	↓ 56.55%

	FY23	Y/Y Change
Profit	$89.3M	↑ 11.61%

	FY24	Y/Y Change
Profit	$178.8M	↑ 100.18%

	FY25	Y/Y Change
Profit	$539.2M	↑ 201.58%

Q1 FY21

Q2 FY21

Q3 FY21

Q1 FY24

Q2 FY24

Q1 FY25

Q2 FY25

Q3 FY25

Q4 FY25

Q1 FY26

	Q1 FY21	Q/Q Change
Profit	$38.6M	-

	Q2 FY21	Q/Q Change
Profit	$42.9M	↑ 11.09%

	Q3 FY21	Q/Q Change
Profit	$54.1M	↑ 26.17%

	Q1 FY24	Q/Q Change
Profit	$26.1M	↓ 51.72%

	Q2 FY24	Q/Q Change
Profit	$37.6M	↑ 43.81%

	Q1 FY25	Q/Q Change
Profit	$57.1M	↑ 51.95%

	Q2 FY25	Q/Q Change
Profit	$113.7M	↑ 99.23%

	Q3 FY25	Q/Q Change
Profit	$147.5M	↑ 29.75%

	Q4 FY25	Q/Q Change
Profit	$220.9M	↑ 49.77%

	Q1 FY26	Q/Q Change
Profit	$141.3M	↓ 36.02%

FY19

FY20

FY22

FY23

FY24

FY25

	FY19	Y/Y Change
Operating Cash Flow	$254.0M	↑ 41.29%
Investing Cash Flow	$-271.9M	↓ 59.02%
Financing Cash Flow	$-108.5M	↓ 121.17%

	FY20	Y/Y Change
Operating Cash Flow	$277.0M	↑ 9.06%
Investing Cash Flow	$-34.0M	↓ 87.51%
Financing Cash Flow	$-249.9M	↑ 130.35%

	FY22	Y/Y Change
Operating Cash Flow	$-285.7M	↓ 203.14%
Investing Cash Flow	$-283.0M	↑ 733.1%
Financing Cash Flow	$10.4M	↓ 104.18%

	FY23	Y/Y Change
Operating Cash Flow	$-276.1M	↓ 3.36%
Investing Cash Flow	$214.8M	↓ 175.9%
Financing Cash Flow	$10.1M	↓ 3.0%

	FY24	Y/Y Change
Operating Cash Flow	$-245.2M	↓ 11.19%
Investing Cash Flow	$52.9M	↓ 75.35%
Financing Cash Flow	$200.3M	↑ 1876.83%

	FY25	Y/Y Change
Operating Cash Flow	$83.2M	↓ 133.91%
Investing Cash Flow	$-16.3M	↓ 130.72%
Financing Cash Flow	$665.0M	↑ 232.01%

Q2 FY24

Q1 FY25

Q2 FY25

Q3 FY25

Q4 FY25

Q1 FY26

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-62.9M	↓ 14.88%
Investing Cash Flow	$-2.6M	↓ 104.34%
Financing Cash Flow	$-129.0K	↓ 100.06%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-31.3M	↓ 50.2%
Investing Cash Flow	$-2.7M	↑ 3.9%
Financing Cash Flow	$1.3M	↓ 1096.12%

	Q1 FY26	Q/Q Change
Operating Cash Flow	$32.9M	↓ 26.58%
Investing Cash Flow	$-10.3M	↑ 103.18%
Financing Cash Flow	$824.0K	↓ 75.76%

Caris Life Sciences Common Stock Technicals Summary

Sell

Neutral

Buy

Caris Life Sciences Common Stock is currently in a neutral trading position according to technical analysis indicators.

Caris Life Sciences, Inc. Common Stock Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Caris Life Sciences, Inc. Common Stock	-6.19%	-34.7%	-40.46%	-40.46%	-61.98%
Regeneron Pharmaceuticals, Inc. Common Stock	-9.45%	-20.34%	2.66%	-14.7%	23.51%
Vertex Pharmaceuticals Incorporated Common Stock	5.84%	3.31%	0.2%	37.71%	113.65%
Alnylam Pharmaceuticals, Inc. Common Stock	1.28%	-32.39%	4.15%	63.61%	111.44%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Caris Life Sciences, Inc. Common Stock	NA	NA	NA	0.15	0.28	0.09	NA	2.1
Regeneron Pharmaceuticals, Inc. Common Stock	15.34	15.34	1.09	46.25	0.15	0.06	0.01	308.33
Vertex Pharmaceuticals Incorporated Common Stock	25.98	25.98	1.64	19.14	0.24	0.12	NA	76.18
Alnylam Pharmaceuticals, Inc. Common Stock	74.09	74.09	0.5	9.53	0.9	0.1	NA	8.06

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Caris Life Sciences, Inc. Common Stock	NA	$4.3B	-61.98%	NA	3.75%
Regeneron Pharmaceuticals, Inc. Common Stock	Buy	$65.8B	23.51%	15.34	29.65%
Vertex Pharmaceuticals Incorporated Common Stock	Buy	$111.0B	113.65%	25.98	35.51%
Alnylam Pharmaceuticals, Inc. Common Stock	Buy	$39.5B	111.44%	74.09	12.55%

Caris Life Sciences Common Stock Dividend announcements

Caris Life Sciences Common Stock Earnings
Caris Life Sciences Common Stock’s price-to-earnings ratio stands at None

About Caris Life Sciences, Inc. Common Stock

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.

Organization	Caris Life Sciences Common Stock
Employees	1846
CEO	Dr. David Dean Halbert M.D.
Industry	Healthcare

Key Management of Caris Life Sciences, Inc. Common Stock

Name	Title
Dr. David Dean Halbert M.D.	Chairman, CEO & Founder
Mr. Brian J. Brille J.D.	Executive Vice Chairman & Executive VP
Dr. David Spetzler M.B.A., M.S., Ph.D.	President
Mr. J. Russel Denton	Senior VP, General Counsel & Secretary
Mr. Luke Power	Senior VP, CFO & Chief Accounting Officer
Mr. Jon Mark Harmon	Senior VP & Chief Operations Officer
Dr. Valeriy Domenyuk	Senior VP & CTO
Dr. Milan Radovich Ph.D.	Senior VP & Chief Scientific Officer
Ms. Ginger Appleberry J.D.	Senior VP, Deputy General Counsel & Chief Compliance Officer
Mr. Narendra Chokshi	Senior Vice President of Corporate Development

Important FAQs about investing in CAI Stock from India :

What is Caris Life Sciences Common Stock share price today?

Caris Life Sciences Common Stock share price today is $16.67 as on May 29, 2026 at 8:54 pm IST at the close of the market. Caris Life Sciences Common Stock share today touched a day high of $16.79 and a low of $15.46.

What is the 52 week high and 52 week low for Caris Life Sciences Common Stock share?

Caris Life Sciences Common Stock share touched a 52 week high of $42.50 and a 52 week low of $14.19. Caris Life Sciences Common Stock stock price today i.e. May 29, 2026 at 8:54 pm IST is closed at $16.67, lower by 60.78% versus the 52 week high.

How to invest in Caris Life Sciences Common Stock Stock (CAI) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Caris Life Sciences Common Stock on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Caris Life Sciences Common Stock Shares that will get you 0.0900 shares as per Caris Life Sciences Common Stock share price of $16.67 per share as on May 29, 2026 at 8:54 pm IST.

What is the minimum amount required to buy Caris Life Sciences Common Stock Stock (CAI) from India?

Indian investors can start investing in Caris Life Sciences Common Stock (CAI) shares with as little as ₹95.6863 or $1 (as of May 29, 2026) using the INDmoney app.
For example: If you want to invest $10 or ₹956.86 in Caris Life Sciences Common Stock stock (as per the Rupee-Dollar exchange rate as on May 29, 2026). Based on Caris Life Sciences Common Stock share’s latest price of $16.67 as on May 29, 2026 at 8:54 pm IST, you will get 0.5999 shares of Caris Life Sciences Common Stock. Learn more about fractional shares .

What are the returns that Caris Life Sciences Common Stock has given to Indian investors in the last 5 years?

Caris Life Sciences Common Stock stock has given -61.98% share price returns and 31.94% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?

Discover More

MiniMed Group, Inc. Common Stock
$11.51
+6.57%
Veradermics, Incorporated
$102.88
+2.75%
Kailera Therapeutics, Inc. Common Stock
$22.94
+4.7%
Axogen, Inc. Common Stock
$40.42
+1.38%
First Busey Corporation Class A Common Stock
$27.25
+0.33%
Laureate Education, Inc. Common Stock
$32.50
-2.31%
Stantec, Inc.
$75.66
+0.25%
OUTFRONT Media Inc.
$32.48
-0.4%
NNN REIT, Inc.
$44.85
+0.02%

Explore all

	Q2 FY25	Q/Q Change
Operating Cash Flow	$7.3M	↓ 123.26%
Investing Cash Flow	$-1.4M	↓ 48.46%
Financing Cash Flow	$681.4M	↑ 52927.39%

	Q3 FY25	Q/Q Change
Operating Cash Flow	$62.4M	↑ 756.55%
Investing Cash Flow	$-7.1M	↑ 411.9%
Financing Cash Flow	$-21.1M	↓ 103.1%

	Q4 FY25	Q/Q Change
Operating Cash Flow	$44.8M	↓ 28.27%
Investing Cash Flow	$-5.1M	↓ 28.26%
Financing Cash Flow	$3.4M	↓ 116.11%

Caris Life Sciences Common Stock Share Price CAI

Caris Life Sciences Common Stock stock performance

Caris Life Sciences Common Stock Stock Returns

Caris Life Sciences, Inc. Common Stock Key Stats

Stock Returns calculator for Caris Life Sciences Common Stock Stock including INR - Dollar returns

Indian investors sentiment towards Caris Life Sciences Common Stock Stock

Global Institutional Holdings in Caris Life Sciences, Inc. Common Stock

Analyst Recommendation on Caris Life Sciences Common Stock Stock

Caris Life Sciences Common Stock Share Price Target

Caris Life Sciences Common Stock Stock Insights

Price Movement

Caris Life Sciences, Inc. Common Stock Financials

Caris Life Sciences Common Stock Technicals Summary

Caris Life Sciences, Inc. Common Stock Vs Peers

Caris Life Sciences Common Stock Dividend announcements

Caris Life Sciences Common Stock Earnings

About Caris Life Sciences, Inc. Common Stock

Key Management of Caris Life Sciences, Inc. Common Stock

Important FAQs about investing in CAI Stock from India :

What is Caris Life Sciences Common Stock share price today?

What is the 52 week high and 52 week low for Caris Life Sciences Common Stock share?

How to invest in Caris Life Sciences Common Stock Stock (CAI) from India?

What is the minimum amount required to buy Caris Life Sciences Common Stock Stock (CAI) from India?

What are the returns that Caris Life Sciences Common Stock has given to Indian investors in the last 5 years?

Discover More